Innocrin Pharmaceuticals (Series D)
Funding Details
- Awarder
- Inbox
- Date Award
- April 15, 2015
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $28,000,000
Company Info
- Organizations Involved
- Novartis Venture Fund, Eshelman Ventures, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, Lurie Holdings, Astellas Venture Management
- Company Description
- Innocrin discovers and develops novel oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of prostate cancer.
- Market
- Castration-resistant prostate cancer and other hormonal excess syndromes
- Location
- Durham, North Carolina, USA
- Coinvestors
- Eshelman Ventures, Hatteras Venture Partners, Intersouth Partners, Novartis Venture Fund